Glyxambi

Active Ingredient(s): Empagliflozin + Linagliptin
FDA Approved: * January 30, 2015
Pharm Company: * BOEHRINGER INGELHEIM
Category: Diabetes

Empagliflozin/linagliptin, sold under the brand name Glyxambi, is a fixed-dose combination anti-diabetic medication used to treat type 2 diabetes.[5][6] It is a combination of empagliflozin and linagliptin.[5][6] It is taken by mouth.[5][6] The most common side effects include urinary infections, nasopharyngitis, and upper respiratory tract infections .[5][6] It was ... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Glyxambi Oral Tablet, Film Coated

NDC: 0597-0164

Labeler:

Boehringer Ingelheim Pharmaceuticals, Inc.

Glyxambi Oral Tablet, Film Coated

NDC: 0597-0182

Labeler:

Boehringer Ingelheim Pharmaceuticals, Inc.

Glyxambi Oral Tablet, Film Coated

NDC: 70518-2046

Labeler:

Remedyrepack Inc.